SEC Company Response from Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Jan 30, 2018
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: Jan. 30, 2018 · CIK: 0001506251 · Accession: 0001213900-18-001023
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-222538
Referenced dates: January 25, 2018
Letter
Re: Citius Pharmaceuticals, Inc.
January 30, 2018
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
F Street N.E.
Washington, DC 20549
Attn: Christine Westbrook
Registration Statement on Form S-1
Filed January 12, 2018
File No. 333-222538
Ladies and Gentlemen:
We write this letter on behalf of our client Citius Pharmaceuticals, Inc. in response to the comment of the Staff of the Securities and Exchange Commission with respect to the above-captioned filing, as set forth in the Staff’s letter dated January 25, 2018. Our response below is numbered to correspond to the numbered comment in the Staff’s letter, which is repeated below in italics.
FORM S-1
Form S-1 Filed January 12, 2018
Incorporation of Certain Documents by Reference, page 63
1. Please revise your disclosure to incorporate by reference your definitive proxy statement filed on December 13, 2017 and current reports on Form 8-K filed on October 10, 2017, October 24, 2017, October 31, 2017, November 7, 2017 (two), November 9, 2017, December 1, 2017 and December 19, 2017. Refer to Item 12(a)(2) of Form S-1.
U.S. Securities and Exchange Commission
January 30, 2018
Page
The requested disclosure has been made on page 63.
* * * * *
Citius Pharmaceuticals, Inc. respectfully submits that the foregoing discussions and amendments to the registration statement are appropriately responsive to the comments of the Staff. If the Staff has any further comments, please direct them to the undersigned.
Sincerely,
/s/ Alexander M. Donaldson
Show Raw Text
CORRESP
1
filename1.htm
January
30, 2018
VIA
EDGAR
Division
of Corporation Finance
U.S.
Securities and Exchange Commission
100
F Street N.E.
Washington,
DC 20549
Attn:
Christine Westbrook
Re: Citius
Pharmaceuticals, Inc.
Registration
Statement on Form S-1
Filed
January 12, 2018
File
No. 333-222538
Ladies
and Gentlemen:
We
write this letter on behalf of our client Citius Pharmaceuticals, Inc. in response to the comment of the Staff of the Securities
and Exchange Commission with respect to the above-captioned filing, as set forth in the Staff’s letter dated January 25,
2018. Our response below is numbered to correspond to the numbered comment in the Staff’s letter, which is repeated below
in italics.
FORM
S-1
Form
S-1 Filed January 12, 2018
Incorporation
of Certain Documents by Reference, page 63
1. Please
revise your disclosure to incorporate by reference your definitive proxy statement filed
on December 13, 2017 and current reports on Form 8-K filed on October 10, 2017, October
24, 2017, October 31, 2017, November 7, 2017 (two), November 9, 2017, December 1, 2017
and December 19, 2017. Refer to Item 12(a)(2) of Form S-1.
U.S.
Securities and Exchange Commission
January
30, 2018
Page
2
The
requested disclosure has been made on page 63.
*
* * * *
Citius
Pharmaceuticals, Inc. respectfully submits that the foregoing discussions and amendments to the registration statement are appropriately
responsive to the comments of the Staff. If the Staff has any further comments, please direct them to the undersigned.
Sincerely,
/s/ Alexander M. Donaldson
cc: Jaime
Bartushak, Chief Financial Officer